Melanotan I is a selective MC1R agonist that drives melanogenesis and photoprotection with minimal MC4R crossover. That selectivity is the point: compared with MT-2, the reported side-effect profile is cleaner, with less nausea and reduced libido and appetite effects. Its close analog afamelanotide is the only alpha-MSH analog to reach FDA approval.
- Selective MC1R activation increases melanin and provides photoprotection, with minimal MC4R involvement.PubMed: Melanotan I
- Its close analog afamelanotide is FDA-approved as Scenesse for a rare disorder in which sunlight is painful, the only approved alpha-MSH analog.DailyMed: afamelanotide
- Cleaner reported profile than MT-2: less nausea, with libido and appetite effects reported as reduced rather than absent.researchdosing
- Straight talk: MT-1 itself is not approved, and it acts more slowly than MT-2.ClinicalTrials: Melanotan I
- Published reviews flag melanoma and mole risk across the class.PubMed: Melanotan I